|AFFILIATION:||Curtana Pharmaceuticals, Inc., Austin, Texas, United States|
Track: Medical & Biotech
Tech Readiness: TRL 3
Tech Brief: CT-179 is a novel, targeted, small molecule therapeutic for the treatment of gliomas, including glioblastoma (GBM) in adults and pediatric high grade glioma (pHGG) in children. CT-179 targets Olig2, a transcription factor that is critical to the formation, growth, and spread of the brain cancer.
Value Proposition: CT-179 has no direct national defense benefit.
Org Type: Mid-stage Startup (A or B)
Booth Number: T515